Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 12/20 | 0.43 |
| ▸ | ARG2 | P78540 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9501854 | 0.88 | ODC1 (0.61) | ODC1ARG1ARG2KDM4ELMNA | |
| SCHEMBL2854826 | 0.85 | ODC1 (0.47) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL5324175 | 0.85 | MEN1 (0.65) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL3256585 | 0.82 | ODC1 (0.50) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL29359936 | 0.79 | ODC1 (0.63) | ODC1ARG1ARG2KDM4ELMNA | |
| SCHEMBL9450990 | 0.79 | NOS1 (0.44) | ODC1MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL23094070 | 0.77 | ODC1 (0.44) | ODC1MEN1CYP1A2KMT2AARG1 | |
| SCHEMBL23094075 | 0.77 | ODC1 (0.44) | ODC1MEN1CYP1A2KMT2AARG1 | |
| SCHEMBL23094069 | 0.77 | ODC1 (0.44) | ODC1MEN1CYP1A2KMT2AARG1 | |
| SCHEMBL11849715 | 0.77 | ODC1 (0.43) | ODC1MEN1ALDH1A1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260535-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2022-12-15 | — | — | WO | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | EBNA1BP2, RPL35, RPL7 | ODC1 1964/4885MEN1 3177/4885ALDH1A1 2249/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | ODC1 346/4885MEN1 2336/4885ALDH1A1 1058/4885 |
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | ODC1 594/4885MEN1 4566/4885ALDH1A1 3811/4885 |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | ADORA1, ADORA3, ADORA2A | ODC1 952/4885MEN1 1018/4885ALDH1A1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.